US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Nexalin Technology, Inc. - Common Stock (NQ:NXL)

3.630 -0.480 (-11.68%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nexalin Technology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs 
From Nexalin Technology, Inc.
Via GlobeNewswire
Friday's session: top gainers and losers ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
DarkHorse CEO Details AI Infrastructure Strategy as DRK Targets Sub-50 MW Compute Opportunity
Via AB Newswire
Topics Artificial Intelligence
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
These stocks are moving in today's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Nexalin Technology Announces Reverse Stock Split
From Nexalin Technology, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
RedChip's Biotech Investor Conference Replays Now Available
Via ACCESS Newswire
News headline image
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
Company Designing FDA Application Amendments and U.S. Clinical Strategy Leveraging Extensive Real-World Neurostimulation Data Sets Reflecting Broad Clinical Experiences 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >